Maintaining weight loss after stopping a GLP-1 medication is genuinely challenging, and significant regain is common.
The STEP-1 extension study on Semaglutide found that participants regained roughly two-thirds of their lost weight within a year of stopping, and similar patterns have been observed with Tirzepatide. The reason is biological rather than a lack of willpower. GLP-1 medications work by addressing the hormonal and appetite signals that drive overeating, and when the medication leaves your system, those signals (increased hunger, less satiety, more food noise) typically return to their pre-treatment baseline. Your body also tends to defend a higher weight set point, meaning it may push hunger up even harder after weight loss.
That said, regain is not inevitable, and many people do hold onto a meaningful portion of their progress with the right strategies. Things that seem to help include:
Some people stay on a low maintenance dose long-term, since these medications are increasingly understood as treatments for a chronic condition rather than short-term tools. Others switch to a less frequent dosing schedule under medical supervision.
If you are thinking about coming off, it is worth talking to your provider about a structured plan, including how to recognize regain early and what your options would be if hunger and food noise return strongly. There is no shame in needing to go back on. Obesity medicine increasingly treats GLP-1s like blood pressure or thyroid medication, where ongoing use is often the right call.
Different ways people phrase this question. Each expands to the same answer.
Maintaining weight loss after stopping a GLP-1 medication is genuinely challenging, and significant regain is common.
The STEP-1 extension study on Semaglutide found that participants regained roughly two-thirds of their lost weight within a year of stopping, and similar patterns have been observed with Tirzepatide. The reason is biological rather than a lack of willpower. GLP-1 medications work by addressing the hormonal and appetite signals that drive overeating, and when the medication leaves your system, those signals (increased hunger, less satiety, more food noise) typically return to their pre-treatment baseline. Your body also tends to defend a higher weight set point, meaning it may push hunger up even harder after weight loss.
That said, regain is not inevitable, and many people do hold onto a meaningful portion of their progress with the right strategies. Things that seem to help include:
Some people stay on a low maintenance dose long-term, since these medications are increasingly understood as treatments for a chronic condition rather than short-term tools. Others switch to a less frequent dosing schedule under medical supervision.
If you are thinking about coming off, it is worth talking to your provider about a structured plan, including how to recognize regain early and what your options would be if hunger and food noise return strongly. There is no shame in needing to go back on. Obesity medicine increasingly treats GLP-1s like blood pressure or thyroid medication, where ongoing use is often the right call.
Maintaining weight loss after stopping a GLP-1 medication is genuinely challenging, and significant regain is common.
The STEP-1 extension study on Semaglutide found that participants regained roughly two-thirds of their lost weight within a year of stopping, and similar patterns have been observed with Tirzepatide. The reason is biological rather than a lack of willpower. GLP-1 medications work by addressing the hormonal and appetite signals that drive overeating, and when the medication leaves your system, those signals (increased hunger, less satiety, more food noise) typically return to their pre-treatment baseline. Your body also tends to defend a higher weight set point, meaning it may push hunger up even harder after weight loss.
That said, regain is not inevitable, and many people do hold onto a meaningful portion of their progress with the right strategies. Things that seem to help include:
Some people stay on a low maintenance dose long-term, since these medications are increasingly understood as treatments for a chronic condition rather than short-term tools. Others switch to a less frequent dosing schedule under medical supervision.
If you are thinking about coming off, it is worth talking to your provider about a structured plan, including how to recognize regain early and what your options would be if hunger and food noise return strongly. There is no shame in needing to go back on. Obesity medicine increasingly treats GLP-1s like blood pressure or thyroid medication, where ongoing use is often the right call.
Maintaining weight loss after stopping a GLP-1 medication is genuinely challenging, and significant regain is common.
The STEP-1 extension study on Semaglutide found that participants regained roughly two-thirds of their lost weight within a year of stopping, and similar patterns have been observed with Tirzepatide. The reason is biological rather than a lack of willpower. GLP-1 medications work by addressing the hormonal and appetite signals that drive overeating, and when the medication leaves your system, those signals (increased hunger, less satiety, more food noise) typically return to their pre-treatment baseline. Your body also tends to defend a higher weight set point, meaning it may push hunger up even harder after weight loss.
That said, regain is not inevitable, and many people do hold onto a meaningful portion of their progress with the right strategies. Things that seem to help include:
Some people stay on a low maintenance dose long-term, since these medications are increasingly understood as treatments for a chronic condition rather than short-term tools. Others switch to a less frequent dosing schedule under medical supervision.
If you are thinking about coming off, it is worth talking to your provider about a structured plan, including how to recognize regain early and what your options would be if hunger and food noise return strongly. There is no shame in needing to go back on. Obesity medicine increasingly treats GLP-1s like blood pressure or thyroid medication, where ongoing use is often the right call.